In Japanese adults with type 2 diabetes switched from basal-bolus insulin, HbA1c change at 24 weeks with liraglutide did not differ significantly from insulin detemir plus sitagliptin.
In plain wordsIn Japanese adults with type 2 diabetes, blood sugar control (HbA1c) after switching to liraglutide was not significantly different from insulin detemir plus sitagliptin.
- Peptide
- Liraglutide
- Outcome
- No significant changeHbA1c change from baseline at 24 weeks
- Study
n: not reported in source
- Comparator
- Insulin detemir plus sitagliptin
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 24 weeksAs given in this study (human).
Measurements
- HbA1c change
- 0.1%
- liraglutide
- HbA1c change
- 0.3%
- detemir
Source sentences
At 24 weeks, the mean changes in HbA1c from baseline were 0.1% ± 0.9% versus 0.3% ± 0.8% in the liraglutide versus detemir groups, respectively (P = .46).
2 context sentences(design, population, supporting numbers)
The primary end point was HbA1c change from baseline to 24 weeks.
In this multicenter, open-label trial, 90 patients whose diabetes had been controlled well or moderately (glycated hemoglobin [HbA1c ] ≤ 7.3%) with basal-bolus insulin regimen were randomly assigned to a liraglutide group or a detemir group and were followed up for 24 weeks.